CL2013002688A1 - Compuestos derivados de 1,4-diazabiciclo[3,2,2]-nonano, quinuclidina, 1-azabiciclo[2,2,2]-octilo sustituidas; y uso como inhibidores de glucosilceramida sintasa, utiles en el tratamiento de enfermedades metabolicas, tales como almacenamiento lisosomico, solo en combinacion con terapia de reemplazo enzimatico y para el tratamiento del cancer. - Google Patents

Compuestos derivados de 1,4-diazabiciclo[3,2,2]-nonano, quinuclidina, 1-azabiciclo[2,2,2]-octilo sustituidas; y uso como inhibidores de glucosilceramida sintasa, utiles en el tratamiento de enfermedades metabolicas, tales como almacenamiento lisosomico, solo en combinacion con terapia de reemplazo enzimatico y para el tratamiento del cancer.

Info

Publication number: CL2013002688A1
Authority: CL; Chile
Prior art keywords: treatment; nonano; quinuclidine; azabicyclo; diazabicyclo
Prior art date: 2011-03-18

Application number

CL2013002688A

Other languages

English (en)

Inventor

Elyse Bourque

Cassandra Celatka

Bradford Hirth

Markus Metz

Zhong Zhao

Renato Skerlj

Yibin Xiang

Katherine Jancisics

John Marshall

Seng Cheng

Ronald Scheule

Mario Cabrera-Salazar

Andrew Good

Original Assignee

Genzyme Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-03-18

Filing date

2013-09-17

Publication date

2014-03-07

2013-09-17 Application filed by Genzyme Corp filed Critical Genzyme Corp

2014-03-07 Publication of CL2013002688A1 publication Critical patent/CL2013002688A1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Obesity (AREA)
Immunology (AREA)
Emergency Medicine (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Hospice & Palliative Care (AREA)
Physical Education & Sports Medicine (AREA)
Child & Adolescent Psychology (AREA)
Pain & Pain Management (AREA)
Communicable Diseases (AREA)
Psychology (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Orthopedic Medicine & Surgery (AREA)
Oncology (AREA)
Heart & Thoracic Surgery (AREA)

CL2013002688A 2011-03-18 2013-09-17 Compuestos derivados de 1,4-diazabiciclo[3,2,2]-nonano, quinuclidina, 1-azabiciclo[2,2,2]-octilo sustituidas; y uso como inhibidores de glucosilceramida sintasa, utiles en el tratamiento de enfermedades metabolicas, tales como almacenamiento lisosomico, solo en combinacion con terapia de reemplazo enzimatico y para el tratamiento del cancer. CL2013002688A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161454034P	2011-03-18	2011-03-18
US201261590711P	2012-01-25	2012-01-25

Publications (1)

Publication Number	Publication Date
CL2013002688A1 true CL2013002688A1 (es)	2014-03-07

Family

ID=46879977

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2013002688A CL2013002688A1 (es)	2011-03-18	2013-09-17	Compuestos derivados de 1,4-diazabiciclo[3,2,2]-nonano, quinuclidina, 1-azabiciclo[2,2,2]-octilo sustituidas; y uso como inhibidores de glucosilceramida sintasa, utiles en el tratamiento de enfermedades metabolicas, tales como almacenamiento lisosomico, solo en combinacion con terapia de reemplazo enzimatico y para el tratamiento del cancer.

Country Status (36)

Country	Link
US (5)	US9139580B2 (es)
EP (2)	EP3673906A1 (es)
JP (2)	JP6117708B2 (es)
KR (1)	KR101987736B1 (es)
CN (2)	CN103917094B (es)
AR (1)	AR085425A1 (es)
AU (2)	AU2012231275A1 (es)
BR (2)	BR112013023774B1 (es)
CA (1)	CA2830540C (es)
CL (1)	CL2013002688A1 (es)
CO (1)	CO6801749A2 (es)
CR (1)	CR20190034A (es)
DK (1)	DK2685986T3 (es)
DO (1)	DOP2013000209A (es)
EC (1)	ECSP13012978A (es)
ES (1)	ES2774293T3 (es)
GT (1)	GT201300215A (es)
HR (1)	HRP20200226T1 (es)
HU (1)	HUE047888T2 (es)
IL (1)	IL228514B (es)
LT (1)	LT2685986T (es)
MA (1)	MA35023B1 (es)
MX (3)	MX365245B (es)
MY (1)	MY173998A (es)
NI (1)	NI201300083A (es)
PE (1)	PE20140412A1 (es)
PL (1)	PL2685986T3 (es)
PT (1)	PT2685986T (es)
RS (1)	RS59963B1 (es)
RU (2)	RU2018104472A (es)
SI (1)	SI2685986T1 (es)
TW (2)	TWI634119B (es)
UA (1)	UA118248C2 (es)
UY (1)	UY33958A (es)
WO (1)	WO2012129084A2 (es)
ZA (1)	ZA201307016B (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI2685986T1 (sl) *	2011-03-18	2020-03-31	Genzyme Corporation	Inhibitor glukozilceramid sintaze
AU2019222801B2 (en) *	2012-09-11	2021-02-18	Genzyme Corporation	Glucosylceramide synthase inhibitors
JOP20130273B1 (ar)	2012-09-11	2021-08-17	Genzyme Corp	مثبطات انزيم (سينثاز) غلوكوسيل سيراميد
CA3092901C (en) *	2013-03-15	2024-01-02	Genzyme Corporation	A method of preparing glucosylceramide synthase quinuclidine carbamate inhibitors
JO3713B1 (ar) *	2013-03-15	2021-01-31	Genzyme Corp	أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت
CN104418851A (zh) *	2013-09-02	2015-03-18	上海龙翔生物医药开发有限公司	奎宁环衍生物的制备方法及纯化方法
ES2871416T3 (es) *	2013-12-11	2021-10-28	Genzyme Corp	Inhibidores de glucosilceramida sintasa
RU2016152499A (ru) *	2014-05-30	2018-07-04	Драг Дискавери Ресеч Сентэ	Новые соединения в качестве противотуберкулезных препаратов
EP3253734B1 (en)	2015-02-02	2020-12-23	The Regents of The University of Michigan	Glucosylceramide synthase inhibitors and therapeutic methods using the same
TW201642855A (zh) *	2015-03-10	2016-12-16	健臻公司	用於治療蛋白質病變之方法
US10167270B2 (en)	2015-07-01	2019-01-01	Northwestern University	Substituted quinazoline compounds and uses thereof for modulating glucocerebrosidase activity
JP2018522872A (ja)	2015-07-01	2018-08-16	ノースウェスタンユニバーシティ	置換４−メチルピロロ［１，２−ａ］ピリミジン−８−カルボキサミド化合物及びグルコセレブロシダーゼ活性の調節のためのその使用
AR107483A1 (es) *	2016-01-29	2018-05-02	Hanmi Pharm Ind Co Ltd	Conjugado de enzimas terapéuticas
MA44484A (fr)	2016-03-25	2019-01-30	Genzyme Corp	Biomarqueurs de protéinopathies et utilisations associées
EP3318277A1 (en)	2016-11-04	2018-05-09	Institut du Cerveau et de la Moelle Epiniere-ICM	Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases
US11001891B2 (en)	2016-11-14	2021-05-11	Berg Llc	Methods for treating Parkinson's disease
CN110494432B (zh)	2016-12-28	2022-08-12	米尼奥尔克斯治疗有限公司	异喹啉化合物，其制备方法及其在与β-半乳糖苷酶活性改变相关的病症中的治疗用途
CA3048357A1 (en)	2016-12-29	2018-07-05	Minoryx Therapeutics S.L.	Heteroaryl compounds and their use
CN108341822B (zh) *	2017-01-23	2021-04-16	广州市恒诺康医药科技有限公司	Fxr受体调节剂及其制备方法和应用
EP3709986B1 (en) *	2017-11-14	2023-11-01	Merck Sharp & Dohme LLC	Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
EP3728265A1 (en)	2017-12-21	2020-10-28	BIAL - BioTech Investments, Inc.	Crystalline substituted cyclohexyl pyrazolo[1,5-a]pyrimidinyl carboxamide compound and therapeutic uses thereof
EP3747885A4 (en) *	2018-01-31	2021-11-03	Takeda Pharmaceutical Company Limited	HETEROCYCLIC CONNECTION
US10519157B2 (en) *	2018-02-09	2019-12-31	X-Cutag Therapeutics, Inc.	Deuterated compounds for treating Fabry, Gaucher, Parkinson's and related diseases and conditions, and compositions and methods thereof
KR102342902B1 (ko) *	2018-11-22	2021-12-24	(주)프로스테믹스	엑소좀 및 이의 다양한 용도
KR102342901B1 (ko) *	2018-11-22	2021-12-24	(주)프로스테믹스	엑소좀 및 이의 다양한 용도
KR102233530B1 (ko) *	2018-11-22	2021-03-31	(주)프로스테믹스	엑소좀 및 이의 다양한 용도
CA3128041A1 (en)	2019-02-04	2020-08-13	Genzyme Corporation	Methods for treating symptoms and disorders associated with lysosomal storage diseases
US20220110922A1 (en)	2019-02-04	2022-04-14	Genzyme Corporation	Treatment of ciliopathies using inhibitors of glucosylceramide synthase (gcs)
WO2020193746A1 (en)	2019-03-28	2020-10-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for predicting the survival of patients suffering from melanoma
JP7539382B2 (ja)	2019-07-29	2024-08-23	武田薬品工業株式会社	複素環化合物
JP2022553107A (ja)	2019-10-23	2022-12-21	ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン	グルコシルセラミドシンターゼ阻害剤およびそれを使用する治療方法
US20220402909A1 (en) *	2019-11-15	2022-12-22	Yuhan Corporation	Novel derivatives having 1,2,3,4-tetrahydronaphthalene moiety or pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same
BR112022009409A2 (pt) *	2019-11-15	2022-08-09	Yuhan Corp	Novos derivados que têm grupamento 2,3-dihidro-1h-indeno ou 2,3-dihidrobenzofurano ou sal farmaceuticamente aceitável dos mesmos e composições farmacêuticas que os compreendem
AU2020393174A1 (en)	2019-11-25	2022-06-30	Gt Gain Therapeutics Sa	Aryl and heteroaryl compounds, and therapeutic uses thereof in conditions associated with the alteration of the activity of galactocerebrosidase
US20230107499A1 (en)	2019-11-25	2023-04-06	Gain Therapeutics Sa	Heteroaryl compounds and therapeutic uses thereof in conditions associated with the alteration of the activity of beta-glucocerebrosidase
AU2021215396A1 (en) *	2020-02-03	2022-09-29	Genzyme Corporation	Methods for treating neurological symptoms associated with lysosomal storage diseases
EP4100015A1 (en)	2020-02-03	2022-12-14	Gain Therapeutics SA	Combination therapy for treating mps1
WO2021214771A1 (en)	2020-04-23	2021-10-28	The Israel Institute of Biological Research (IIBR)	Glucosylceramide synthase inhibitors for prevention and treatment of viral diseases
WO2021221953A1 (en)	2020-04-28	2021-11-04	The Regents Of The University Of Michigan	Pyridine inhibitors of glucosylceramide synthase and therapeutic methods using the same
CN116133647A (zh)	2020-07-24	2023-05-16	建新公司	包含文鲁司他的药物组合物
WO2022240116A1 (en) *	2021-05-11	2022-11-17	Yuhan Corporation	Novel compounds having inhibitory activity against glucosylceramide synthase or pharmaceutically acceptable salt thereof, processes for preparing the same, and pharmaceutical compositions comprising the same
WO2023042177A1 (en)	2021-09-20	2023-03-23	Gt Gain Therapeutics Sa	Enantiomers of 5-((7-chloroisoquinolin-1-yl)amino)-n-(6-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)picolinamide
WO2023239892A1 (en) *	2022-06-10	2023-12-14	Arkuda Therapeutics	Compounds for modulation of cd68 and uses thereof
WO2024090919A1 (en) *	2022-10-24	2024-05-02	Yuhan Corporation	Improved processes for preparing dimethyl-2,3-dihydro-1h-indene derivatives
KR20240057364A (ko) *	2022-10-24	2024-05-02	주식회사유한양행	다이메틸-2,3-다이하이드로-1h-인덴 유도체의 신규 염 및 이의 제조방법
TW202430159A (zh)	2022-12-01	2024-08-01	美商健臻公司	使用葡萄糖神經醯胺合成酶抑制劑的治療方法
WO2024141998A1 (en)	2022-12-30	2024-07-04	Gt Gain Therapeutics Sa	Method of treating tauopathies
CN118496159B (zh) *	2024-07-18	2024-09-24	广州医科大学附属市八医院	一种化合物在制备具有预防和/或治疗肝纤维化作用的药物中的应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE640616A (es)	1962-12-19
US3492397A (en)	1967-04-07	1970-01-27	Warner Lambert Pharmaceutical	Sustained release dosage in the pellet form and process thereof
US4060598A (en)	1967-06-28	1977-11-29	Boehringer Mannheim G.M.B.H.	Tablets coated with aqueous resin dispersions
US3538214A (en)	1969-04-22	1970-11-03	Merck & Co Inc	Controlled release medicinal tablets
US4173626A (en)	1978-12-11	1979-11-06	Merck & Co., Inc.	Sustained release indomethacin
BR8707474A (pt) *	1986-10-03	1988-09-13	Micro Motion Inc	Medidor de velocidade de fluxo de massa de coriolis de densidade insensivel
IE62231B1 (en)	1987-12-24	1995-01-11	Wyeth John & Brother Ltd	Heterocyclic compounds
US5236838A (en)	1988-12-23	1993-08-17	Genzyme Corporation	Enzymatically active recombinant glucocerebrosidase
US5549892A (en)	1988-12-23	1996-08-27	Genzyme Corporation	Enhanced in vivo uptake of glucocerebrosidase
IT1228293B (it) *	1989-02-06	1991-06-07	Angeli Inst Spa	Benzoderivati di composti eterociclici contenenti azoto.
US5272071A (en)	1989-12-22	1993-12-21	Applied Research Systems Ars Holding N.V.	Method for the modification of the expression characteristics of an endogenous gene of a given cell line
US5968502A (en)	1991-11-05	1999-10-19	Transkaryotic Therapies, Inc.	Protein production and protein delivery
EP0747355A4 (en)	1994-02-10	1997-04-09	Yamanouchi Pharma Co Ltd	NEW CARBAMATES AND MEDICINAL PRODUCTS CONTAINING THEM
JPH08198751A (ja) *	1995-01-19	1996-08-06	Yamanouchi Pharmaceut Co Ltd	カルバメート誘導体
US5668144A (en) *	1995-11-08	1997-09-16	American Home Products Corporation	1-azabicyclopheptane derivatives
CA2305768A1 (en)	1997-10-29	2000-02-24	Genzyme Corporation	Compositions and methods for treating lysosomal storage disease
US6953855B2 (en) *	1998-12-11	2005-10-11	Targacept, Inc.	3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
FR2791678B1 (fr) *	1999-03-30	2001-05-04	Synthelabo	Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique
GB0010955D0 (en) *	2000-05-05	2000-06-28	Novartis Ag	Organic compounds
RU2296762C2 (ru) *	2000-12-22	2007-04-10	Альмиралль Продесфарма Аг	Карбаматы хинуклидина, способы их получения и фармацевтическая композиция на их основе
ATE348829T1 (de) *	2001-02-06	2007-01-15	Pfizer Prod Inc	Pharmazeutische zusammensetzungen zur behandlung von störungen des zns oder anderen erkrankungen
JP2003267977A (ja) *	2002-03-14	2003-09-25	Yamanouchi Pharmaceut Co Ltd	キヌクリジン誘導体
ES2203327B1 (es) *	2002-06-21	2005-06-16	Almirall Prodesfarma, S.A.	Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
CA2492404C (en) *	2002-07-17	2012-02-07	Oxford Glycosciences (Uk) Ltd	Piperidinetriol derivatives as inhibitors of glycosylceramide synthase
WO2004011430A1 (ja) *	2002-07-25	2004-02-05	Yamanouchi Pharmaceutical Co., Ltd.	ナトリウムチャネル阻害剤
SE0202598D0 (sv) *	2002-09-02	2002-09-02	Astrazeneca Ab	Alpha-7 Nicotinic receptor agonists and statins in combination
ES2293086T3 (es) *	2002-12-06	2008-03-16	The Feinstein Institute For Medical Research	Inhibicion de la inflamacion usando agonistas colinergicos de union al receptor alfa 7.
GB0400812D0 (en)	2004-01-14	2004-02-18	Celltech R&D Ltd	Novel compounds
JP2007186422A (ja) *	2004-01-28	2007-07-26	Astellas Pharma Inc	アリールスルフィド誘導体
EP1773304A2 (en) *	2004-06-23	2007-04-18	The Feinstein Institute for Medical Research	Method of treating ileus by pharmacological activation of cholinergic receptors
BRPI0517701A8 (pt)	2004-11-10	2018-01-23	Genzyme Corp	métodos de tratamento de diabetes mellitus
WO2007100430A2 (en) *	2006-01-27	2007-09-07	Yale University	Cytisine and acetylcholine analogs and methods of treating mood disorders
US7840109B2 (en) *	2006-08-14	2010-11-23	Adc Telecommunications, Inc.	Factory spliced cable assembly
CA2706727A1 (en) *	2007-11-29	2009-06-11	Michael S. Mcgrath	Compositions and methods for treating lysosomal disorders
CA2731685A1 (en) *	2008-07-28	2010-02-04	Genzyme Corporation	Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
US20110237538A1 (en) *	2008-08-06	2011-09-29	Summit Corporation Plc	Treatment of lysosomal storage disorders and other proteostatic diseases
EP2154136A1 (en) *	2008-08-08	2010-02-17	CHIESI FARMACEUTICI S.p.A.	Quinuclidine carbonate derivatives and medicinal compositions thereof
WO2010091104A1 (en) *	2009-02-06	2010-08-12	Exelixis, Inc.	Glucosylceramide synthase inhibitors
WO2010091164A1 (en) *	2009-02-06	2010-08-12	Exelixis, Inc.	Inhibitors of glucosylceramide synthase
US20100242354A1 (en) *	2009-06-09	2010-09-30	Sundrop Fuels, Inc.	Systems and methods for reactor chemistry and control
TR201911293T4 (tr)	2009-08-28	2019-08-21	Genzyme Corp	Asit sfingomiyelinaz yetmezliğinin tedavi edilmesine yönelik doz artırımlı enzim repleasman terapisi.
SI2685986T1 (sl) *	2011-03-18	2020-03-31	Genzyme Corporation	Inhibitor glukozilceramid sintaze

2012
- 2012-03-16 SI SI201231727T patent/SI2685986T1/sl unknown
- 2012-03-16 WO PCT/US2012/029417 patent/WO2012129084A2/en active Application Filing
- 2012-03-16 DK DK12760259.7T patent/DK2685986T3/da active
- 2012-03-16 CA CA2830540A patent/CA2830540C/en active Active
- 2012-03-16 BR BR112013023774-0A patent/BR112013023774B1/pt active IP Right Grant
- 2012-03-16 PT PT127602597T patent/PT2685986T/pt unknown
- 2012-03-16 RS RS20200222A patent/RS59963B1/sr unknown
- 2012-03-16 TW TW105121161A patent/TWI634119B/zh active
- 2012-03-16 ES ES12760259T patent/ES2774293T3/es active Active
- 2012-03-16 KR KR1020137027592A patent/KR101987736B1/ko active IP Right Grant
- 2012-03-16 MA MA36299A patent/MA35023B1/fr unknown
- 2012-03-16 CR CR20190034A patent/CR20190034A/es unknown
- 2012-03-16 HU HUE12760259A patent/HUE047888T2/hu unknown
- 2012-03-16 JP JP2013558205A patent/JP6117708B2/ja active Active
- 2012-03-16 MX MX2013010710A patent/MX365245B/es active IP Right Grant
- 2012-03-16 RU RU2018104472A patent/RU2018104472A/ru not_active Application Discontinuation
- 2012-03-16 PE PE2013002075A patent/PE20140412A1/es active IP Right Grant
- 2012-03-16 CN CN201280024127.6A patent/CN103917094B/zh active Active
- 2012-03-16 CN CN201610884699.1A patent/CN107080747B/zh active Active
- 2012-03-16 LT LTEP12760259.7T patent/LT2685986T/lt unknown
- 2012-03-16 AR ARP120100873 patent/AR085425A1/es active IP Right Grant
- 2012-03-16 UA UAA201312420A patent/UA118248C2/uk unknown
- 2012-03-16 MY MYPI2013003389A patent/MY173998A/en unknown
- 2012-03-16 AU AU2012231275A patent/AU2012231275A1/en not_active Abandoned
- 2012-03-16 TW TW101109086A patent/TWI546301B/zh active
- 2012-03-16 RU RU2013146550A patent/RU2645675C2/ru active
- 2012-03-16 UY UY33958A patent/UY33958A/es not_active Application Discontinuation
- 2012-03-16 BR BR122019017719-8A patent/BR122019017719B1/pt active IP Right Grant
- 2012-03-16 EP EP19207540.6A patent/EP3673906A1/en active Pending
- 2012-03-16 PL PL12760259T patent/PL2685986T3/pl unknown
- 2012-03-16 MX MX2018007961A patent/MX368340B/es unknown
- 2012-03-16 EP EP12760259.7A patent/EP2685986B1/en active Active
2013
- 2013-09-17 IL IL228514A patent/IL228514B/en active IP Right Grant
- 2013-09-17 NI NI201300083A patent/NI201300083A/es unknown
- 2013-09-17 DO DO2013000209A patent/DOP2013000209A/es unknown
- 2013-09-17 CL CL2013002688A patent/CL2013002688A1/es unknown
- 2013-09-18 MX MX2019008428A patent/MX2019008428A/es unknown
- 2013-09-18 GT GT201300215A patent/GT201300215A/es unknown
- 2013-09-18 ZA ZA2013/07016A patent/ZA201307016B/en unknown
- 2013-09-18 US US14/030,725 patent/US9139580B2/en active Active
- 2013-10-17 CO CO13246820A patent/CO6801749A2/es active IP Right Grant
- 2013-10-17 EC ECSP13012978 patent/ECSP13012978A/es unknown
2014
- 2014-08-28 US US14/471,958 patent/US9126993B2/en active Active
2015
- 2015-08-25 US US14/835,402 patent/US20160207933A1/en not_active Abandoned
2016
- 2016-10-14 AU AU2016244305A patent/AU2016244305B2/en active Active
2017
- 2017-03-22 JP JP2017055577A patent/JP6420860B2/ja active Active
2019
- 2019-08-15 US US16/542,166 patent/US20200048266A1/en not_active Abandoned
2020
- 2020-02-11 HR HRP20200226TT patent/HRP20200226T1/hr unknown
2021
- 2021-04-27 US US17/242,016 patent/US20210261557A1/en active Pending

Also Published As

Publication number	Publication date
EP3673906A1 (en)	2020-07-01
CN103917094B (zh)	2016-11-09
WO2012129084A2 (en)	2012-09-27
US20210261557A1 (en)	2021-08-26
RU2013146550A (ru)	2015-04-27
BR112013023774B1 (pt)	2022-01-11
JP6117708B2 (ja)	2017-04-19
DOP2013000209A (es)	2014-04-15
MA35023B1 (fr)	2014-04-03
MX365245B (es)	2019-05-28
CN103917094A (zh)	2014-07-09
RU2018104472A (ru)	2019-02-22
CN107080747A (zh)	2017-08-22
MX368340B (es)	2019-09-30
KR20140092239A (ko)	2014-07-23
US9139580B2 (en)	2015-09-22
EP2685986B1 (en)	2019-11-27
AR085425A1 (es)	2013-10-02
CN107080747B (zh)	2021-02-26
CO6801749A2 (es)	2013-11-29
AU2016244305A1 (en)	2016-11-03
PL2685986T3 (pl)	2020-07-27
BR112013023774A2 (pt)	2016-12-06
US9126993B2 (en)	2015-09-08
ZA201307016B (en)	2014-05-28
IL228514B (en)	2019-09-26
CA2830540C (en)	2021-04-27
EP2685986A4 (en)	2015-03-04
RU2018104472A3 (es)	2021-04-30
US20200048266A1 (en)	2020-02-13
JP2017141255A (ja)	2017-08-17
NZ615857A (en)	2016-08-26
PE20140412A1 (es)	2014-04-01
MY173998A (en)	2020-03-03
UA118248C2 (uk)	2018-12-26
JP6420860B2 (ja)	2018-11-07
US20160207933A1 (en)	2016-07-21
ECSP13012978A (es)	2015-04-30
TW201716404A (zh)	2017-05-16
BR122019017719B1 (pt)	2022-08-23
IL228514A0 (en)	2013-12-31
UY33958A (es)	2012-10-31
NI201300083A (es)	2014-02-28
TWI634119B (zh)	2018-09-01
GT201300215A (es)	2015-02-09
ES2774293T3 (es)	2020-07-20
WO2012129084A3 (en)	2014-04-24
MX2019008428A (es)	2019-10-30
PT2685986T (pt)	2020-03-05
JP2014517808A (ja)	2014-07-24
CA2830540A1 (en)	2012-09-27
SI2685986T1 (sl)	2020-03-31
AU2016244305B2 (en)	2018-05-24
HRP20200226T1 (hr)	2020-05-29
US20140255381A1 (en)	2014-09-11
AU2012231275A1 (en)	2013-10-17
TWI546301B (zh)	2016-08-21
EP2685986A2 (en)	2014-01-22
MX2013010710A (es)	2013-10-17
RU2645675C2 (ru)	2018-02-27
CR20190034A (es)	2019-05-20
RS59963B1 (sr)	2020-03-31
HUE047888T2 (hu)	2020-05-28
DK2685986T3 (da)	2020-03-02
US20140371460A1 (en)	2014-12-18
KR101987736B1 (ko)	2019-06-11
TW201300383A (zh)	2013-01-01
LT2685986T (lt)	2020-03-10

Publication	Publication Date	Title
CL2013002688A1 (es)	2014-03-07	Compuestos derivados de 1,4-diazabiciclo[3,2,2]-nonano, quinuclidina, 1-azabiciclo[2,2,2]-octilo sustituidas; y uso como inhibidores de glucosilceramida sintasa, utiles en el tratamiento de enfermedades metabolicas, tales como almacenamiento lisosomico, solo en combinacion con terapia de reemplazo enzimatico y para el tratamiento del cancer.
DOP2015000039A (es)	2015-04-15	Inhibidores de glucosilceramida sintasa
CL2015001731A1 (es)	2015-08-28	Compuestos inhibidores de autotaxina; composicion y combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como fibrosis, prurito, cancer, entre otras.
CL2014001752A1 (es)	2014-10-10	Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras.
ECSP14030098A (es)	2016-01-29	Formas cristalinas de un modulador del receptor androgénico
DOP2013000192A (es)	2014-01-31	Compuestos y composiciones como inhibidores de la trk
BR112012004377A2 (pt)	2017-12-12	terapia de reposição enzimática com progressão de dose para tratamento de deficiência de esfingomielinase ácida.
MX2014000129A (es)	2014-05-28	Combinaciones de farmacos y su usos en el tratamiento de una condicion de tos.
SG10201804952QA (en)	2018-07-30	Glucosylceramide synthase inhibitors
CL2014000641A1 (es)	2014-11-14	Compuestos derivados de triazolo[1,5-a]piridina, inhibidores de la ped10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de enfermedades tales como esquizofrenia, parkinson, alzheimer, entre otras.
MX340574B (es)	2016-07-13	Imidazo pirazinas.
BR112015020667A2 (pt)	2017-07-18	método de preparar inibidores de glucosilceramida sintase
UY35439A (es)	2014-10-31	Formas salinas del (2-(2-(4-fluorofenil)tiazol-4-il)propan-2-il)carbamato de (S)-quinuclidin-3-ilo.
EP2743343A4 (en)	2015-03-18	SPRAY FORMULATION OF MESENCHYMAL STEM CELLS FOR THE TREATMENT OF CHRONIC WOUNDS
TN2013000368A1 (en)	2015-01-20	Glucosylceramide synthase inhibitors
UA59700U (ru)	2011-05-25	Способ лечения метаболического синдрома